Financial Data and Key Metrics Changes - The company reported $43 billion in revenue for FY 2025, with a strong double-digit performance and a 10% comprehensive annual growth in revenue [17][23] - Adjusted EPS growth was noted at 12% annually, alongside a similar growth rate in free cash flow generation [23] Business Line Data and Key Metrics Changes - The largest end market for the company is pharmaceutical and biotech, with significant presence in academic, government diagnostics, healthcare, and industrial markets [18][20] - Over 80% of the company's revenue is derived from services and consumables, indicating a recurring revenue business model [20] Market Data and Key Metrics Changes - Approximately half of the company's business is in North America, with a quarter in Europe and the remainder spread across Asia Pacific and Latin America [20] Company Strategy and Development Direction - The company focuses on creating differentiated value for stakeholders, emphasizing sustainable value creation and corporate social responsibility [17][21] - The PPI business system has been in place for over two decades, providing a competitive advantage and enabling successful acquisitions [22] Management's Comments on Operating Environment and Future Outlook - The management expects a continuing recovery in end markets with an anticipated organic growth of around 3% to 4% [27] - The impact of tariffs and cuts to academic research funding is expected to be a headwind of about 1.5% on growth and earnings, although recent developments suggest a lessening impact [27][28] Other Important Information - The advisory resolution approving executive compensation was not approved, indicating shareholder concerns regarding executive pay [15][16] Q&A Session Summary Question: How does the Compensation Committee use the compensation actually paid total compensation figures in its calculation of the CEO target total compensation award for the upcoming year? - The compensation committee considers various factors including benchmarking information, company performance, and shareholder feedback to ensure alignment with compensation philosophy and strategic market positioning [25][26] Question: How will tariffs and cuts to academic research funding impact the company? - The management noted that tariffs and funding cuts are expected to be a headwind of about 1.5% on growth and earnings, but recent developments suggest a lessening impact [27][28]

导读： 瑞孚迪2025年Q1收入6.65亿美元，去年同期收入为6.50亿美元，同比增长2.28%。2025年Q1净利润4223.70万美元，去年同期净利润为2601.30万美 元，同比增长62.37%。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 日 ， 瑞 孚 迪 （ Re v v it y ） 发 布 2 0 2 5 年 一 季 度 财 报 。 2 0 2 5 财 年 第 一 季 度 收 入 6 . 6 5 亿 美 元 ， 去 年 同 期 收 入 为 6 . 5 0 亿 美 元 ， 同 比 增 长 2 . 2 8% 。 2 0 2 5财年第一季度净利润4 2 2 3 . 7 0万美元，去年同期净利润为2 6 0 1 . 3 0万美元，同比增长6 2 . 3 7%。 从业务板块来看，生命科学收入从去年同期的 3 . 3 6 5 亿美元增长 1% 至 3 . 4 0 4 亿美元。制药/生物技术领域的生命科学解决方案（LSD）实现 增长，学术/政府领域的 LSD 出现下滑。生命科学解决方案业务呈低个位数（LSD）下滑， 仪器业务下滑部 ...